BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
376.63
+10.81 (2.96%)
At close: Nov 17, 2025, 4:00 PM EST
370.20
-6.43 (-1.71%)
Pre-market: Nov 18, 2025, 4:01 AM EST
BeOne Medicines AG Employees
BeOne Medicines AG had 11,000 employees as of December 31, 2024. The number of employees increased by 400 or 3.77% compared to the previous year.
Employees
11,000
Change (1Y)
400
Growth (1Y)
3.77%
Revenue / Employee
$454,408
Profits / Employee
$3,000
Market Cap
41.68B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11,000 | 400 | 3.77% |
| Dec 31, 2023 | 10,600 | 1,600 | 17.78% |
| Dec 31, 2022 | 9,000 | 1,000 | 12.50% |
| Dec 31, 2021 | 8,000 | 2,700 | 50.94% |
| Dec 31, 2020 | 5,300 | 1,800 | 51.43% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ONC News
- 15 hours ago - BeOne Medicines AG (ONC) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 23 hours ago - Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma - Business Wire
- 7 days ago - BeOne Medicines AG (ONC) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript - Seeking Alpha
- 11 days ago - BeOne Medicines AG (ONC) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates - Business Wire
- 21 days ago - BeOne Medicines to Present at Upcoming Investor Conferences - Business Wire
- 27 days ago - BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6 - Business Wire
- 4 weeks ago - BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025 - Business Wire